Ontrak Health Achieves HITRUST CSF® Certification for 2024
Ontrak, Inc. (NASDAQ: OTRK), a top AI-driven and telehealth-enabled behavioral healthcare company, has earned HITRUST Risk-based, 2-year (r2) certification for the customer data exchange components of its Ontrak Advanced Engagement System. This certification highlights Ontrak’s steadfast dedication to upholding the…
KalVista’s Sebetralstat Approved by EMA for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE). The application will…
Francisco Partners Sells QGenda to Hearst
Francisco Partners, a global investment firm specializing in technology and healthcare, has announced the sale of QGenda to Hearst. Financial terms of the deal were not disclosed. QGenda, a leader in healthcare workforce management, serves over 700,000 providers across 45…
Syros Updates on SELECT-AML-1 Phase 2 Trial
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet regimen of venetoclax and azacitidine for newly diagnosed, unfit AML…
Pulse Biosciences Appoints Paul LaViolette to Board of Directors
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette will serve as Co-Chairman alongside Robert W. Duggan, bringing his expertise as an independent director to the role. Pulse Biosciences…
Lobe Sciences Announces New Board and Executive Team
Lobe Sciences Ltd (CSE: LOBE, OTCQB: LOBEF) has announced the election of a new board of directors following its annual general meeting. Shareholders elected Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet to the board. Additionally, Mr.…
Astria Therapeutics Selects Ypsomed’s YpsoMate for STAR-0215 in Hereditary Angioedema Treatment
Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company dedicated to advancing treatments for allergic and immunological diseases, has announced its partnership with Ypsomed for developing an autoinjector for STAR-0215. This collaboration aims to enhance the delivery system for STAR-0215, a…
Tandem Diabetes Updates on March 2024 Nationwide Recall of tiOS App
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has provided an update regarding the March 2024 recall of its t:connect mobile app for Apple iOS devices. The recall addresses an issue causing rapid depletion of the t:slim X2 insulin pump battery, potentially…
Zura Bio Completes Exchange Offer, Consent Solicitation, and Warrant Exercise
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company specializing in dual-pathway antibodies for autoimmune and inflammatory diseases, has completed its exchange offer and consent solicitation for its outstanding IPO warrants. This includes both public warrants, which trade under the…
Masimo W1® Watch Gets FDA 510(k) Clearance for Masimo SafetyNet® Connectivity
Masimo (NASDAQ: MASI) has announced that the Masimo W1® medical watch has received FDA 510(k) clearance for integration with the Masimo SafetyNet® telemonitoring system. The Masimo W1®—the first medical watch to offer continuous oxygen saturation (SpO2) and pulse rate (PR)…
UptimeHealth and Darby Dental Supply Launch Darby Dispatch to Boost Dental Practice Efficiency
UptimeHealth, a leader in healthcare technology solutions, is excited to announce a new partnership with Darby Dental Supply, a major dental distributor in the U.S. This collaboration represents a major advancement in improving operational efficiency and compliance for dental practices…
Alpha Cognition Q2 & H1 2024 Financial Results and Corporate Update
Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) has announced its financial results for the second quarter and six months ending June 30, 2024, along with a corporate update. CEO Michael McFadden highlighted the FDA’s approval of ZUNVEYL, a major achievement…